JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, biopharmaceuticals, medical equipment, regenerative medicines, and drug substances in Japan. The comany offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature;...
JCR Pharmaceuticals reported revenue of 33.07 billion JPY for fiscal year 2025, down 22.9% from fiscal year 2024, and net income of -4.76 billion JPY.
Figures from company filings; latest fiscal year ended March 31, 2025.
No profile data available.